<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" content="Piramal Pharma Solutions (PPS), a leading Contract Development and Manufacturing Organization (CDMO), held a special event to introduce the new and expanded manufacturing capabilities at its facilities in Lexington, Kentucky. The inaugural event was attended by Governor Matt Bevin, Piramal Group Chairman Ajay Piramal, and Piramal Pharma Solutions CEO, Vivek Sharma.” data-reactid=”6″ style=”margin: 0px 0px 1em; color: rgb(38, 40, 42); font-family: ‘Helvetica Neue’, Helvetica, Arial, sans-serif; font-size: 15px;” type=”text”> Piramal Pharma Solutions (PPS) has introduced new and expanded manufacturing capabilities at its facilities in Lexington, KY following a $25 million investment. 

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" content="     (Logo: http://mma.prnewswire.com/media/480020/Piramal_Pharma_Solutions_logo_Logo.jpg )
” data-reactid=”7″ style=”margin: 0px 0px 1em; color: rgb(38, 40, 42); font-family: ‘Helvetica Neue’, Helvetica, Arial, sans-serif; font-size: 15px;” type=”text”> The company develops and manufactures sterile finished dosage forms at the Lexington site using isolator technology. The expanded capacity and capabilities in manufacturing, is being rolled out in phases. The first of which is now complete and includes the installation of a new high-speed vial filling line, expansion of laboratories, and associated utility support. The new filling line will double the capacity at Lexington, as well as enhance efficiency and productivity. A large portion of the new capacity has been committed to current clients to support commercial product launches. The next phase includes expanding lyophilization capability and is expected to be operational by the end of 2018.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" content=""With the completion of this first phase of expansion at Lexington, Piramal Pharma Solutions expects to support our customer product launches that address a broad range of adverse human conditions ranging from cancers to pre-term labor to rare childhood diseases. It is our privilege to partner with customers as they seek to improve the quality of life of patients and we thank them for their continued trust and faith in us," said Vivek Sharma, CEO, Piramal Pharma Solutions. He added, “We continue to focus on customer delight and execute on our strategy of becoming the ‘partner of choice’ for our customers, who lever Piramal’s unique broad based capabilities for both integrated offerings and standalone drug substance or drug product offerings. Our world class talent at Lexington will be a key driver in ensuring that we sustainably delight our global customer base.”” data-reactid=”11″ style=”margin: 0px 0px 1em; color: rgb(38, 40, 42); font-family: ‘Helvetica Neue’, Helvetica, Arial, sans-serif; font-size: 15px;” type=”text”> “With the completion of this first phase of expansion at Lexington, Piramal Pharma Solutions expects to support our customer product launches that address a broad range of adverse human conditions ranging from cancers to pre-term labor to rare childhood diseases. It is our privilege to partner with customers as they seek to improve the quality of life of patients and we thank them for their continued trust and faith in us,” said Vivek Sharmachief executive officer of Piramal Pharma Solutions. “We continue to focus on customer delight and execute on our strategy of becoming the ‘partner of choice’ for our customers, who lever Piramal’s unique broad based capabilities for both integrated offerings and standalone drug substance or drug product offerings. Our world class talent at Lexington will be a key driver in ensuring that we sustainably delight our global customer base.”